Waldenström Macroglobulinemia

Review of Pathogenesis and Management

Seongseok Yun, Ariel C. Johnson, Onyemaechi N. Okolo, Stacy J. Arnold, Ali McBride, Ling Zhang, Rachid C. Baz, Faiz - Anwer

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Waldenström macroglobulinemia (WM) is a low-grade B-cell clonal disorder characterized by lymphoplasmacytic bone marrow involvement associated with monoclonal immunoglobulin M. Although WM remains to be an incurable disease with a heterogeneous clinical course, the recent discovery of mutations in the MYD88 and CXCR4 genes further enhanced our understanding of its pathogenesis. Development of new therapies including monoclonal antibodies, proteasome inhibitors, and Bruton tyrosine kinase inhibitors have made the management of WM increasingly complex. Treatment should be tailored to the individual patient while considering many clinical factors. The clinical outcomes are expected to continue to improve, given the emergence of novel therapeutics and better understanding of the underlying pathogenesis.

Original languageEnglish (US)
JournalClinical Lymphoma, Myeloma and Leukemia
DOIs
StateAccepted/In press - Oct 14 2016

Fingerprint

Waldenstrom Macroglobulinemia
Proteasome Inhibitors
Immunoglobulin M
B-Lymphocytes
Therapeutics
Bone Marrow
Monoclonal Antibodies
Mutation
Genes

Keywords

  • CXCR4
  • Lymphoid neoplasm
  • Lymphoplasmacytic lymphoma
  • Monoclonal immunoglobulin M
  • MYD88

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Waldenström Macroglobulinemia : Review of Pathogenesis and Management. / Yun, Seongseok; Johnson, Ariel C.; Okolo, Onyemaechi N.; Arnold, Stacy J.; McBride, Ali; Zhang, Ling; Baz, Rachid C.; Anwer, Faiz -.

In: Clinical Lymphoma, Myeloma and Leukemia, 14.10.2016.

Research output: Contribution to journalArticle

Yun, Seongseok ; Johnson, Ariel C. ; Okolo, Onyemaechi N. ; Arnold, Stacy J. ; McBride, Ali ; Zhang, Ling ; Baz, Rachid C. ; Anwer, Faiz -. / Waldenström Macroglobulinemia : Review of Pathogenesis and Management. In: Clinical Lymphoma, Myeloma and Leukemia. 2016.
@article{186a91250cb8431692ee0cb8a4e5cca9,
title = "Waldenstr{\"o}m Macroglobulinemia: Review of Pathogenesis and Management",
abstract = "Waldenstr{\"o}m macroglobulinemia (WM) is a low-grade B-cell clonal disorder characterized by lymphoplasmacytic bone marrow involvement associated with monoclonal immunoglobulin M. Although WM remains to be an incurable disease with a heterogeneous clinical course, the recent discovery of mutations in the MYD88 and CXCR4 genes further enhanced our understanding of its pathogenesis. Development of new therapies including monoclonal antibodies, proteasome inhibitors, and Bruton tyrosine kinase inhibitors have made the management of WM increasingly complex. Treatment should be tailored to the individual patient while considering many clinical factors. The clinical outcomes are expected to continue to improve, given the emergence of novel therapeutics and better understanding of the underlying pathogenesis.",
keywords = "CXCR4, Lymphoid neoplasm, Lymphoplasmacytic lymphoma, Monoclonal immunoglobulin M, MYD88",
author = "Seongseok Yun and Johnson, {Ariel C.} and Okolo, {Onyemaechi N.} and Arnold, {Stacy J.} and Ali McBride and Ling Zhang and Baz, {Rachid C.} and Anwer, {Faiz -}",
year = "2016",
month = "10",
day = "14",
doi = "10.1016/j.clml.2017.02.028",
language = "English (US)",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",

}

TY - JOUR

T1 - Waldenström Macroglobulinemia

T2 - Review of Pathogenesis and Management

AU - Yun, Seongseok

AU - Johnson, Ariel C.

AU - Okolo, Onyemaechi N.

AU - Arnold, Stacy J.

AU - McBride, Ali

AU - Zhang, Ling

AU - Baz, Rachid C.

AU - Anwer, Faiz -

PY - 2016/10/14

Y1 - 2016/10/14

N2 - Waldenström macroglobulinemia (WM) is a low-grade B-cell clonal disorder characterized by lymphoplasmacytic bone marrow involvement associated with monoclonal immunoglobulin M. Although WM remains to be an incurable disease with a heterogeneous clinical course, the recent discovery of mutations in the MYD88 and CXCR4 genes further enhanced our understanding of its pathogenesis. Development of new therapies including monoclonal antibodies, proteasome inhibitors, and Bruton tyrosine kinase inhibitors have made the management of WM increasingly complex. Treatment should be tailored to the individual patient while considering many clinical factors. The clinical outcomes are expected to continue to improve, given the emergence of novel therapeutics and better understanding of the underlying pathogenesis.

AB - Waldenström macroglobulinemia (WM) is a low-grade B-cell clonal disorder characterized by lymphoplasmacytic bone marrow involvement associated with monoclonal immunoglobulin M. Although WM remains to be an incurable disease with a heterogeneous clinical course, the recent discovery of mutations in the MYD88 and CXCR4 genes further enhanced our understanding of its pathogenesis. Development of new therapies including monoclonal antibodies, proteasome inhibitors, and Bruton tyrosine kinase inhibitors have made the management of WM increasingly complex. Treatment should be tailored to the individual patient while considering many clinical factors. The clinical outcomes are expected to continue to improve, given the emergence of novel therapeutics and better understanding of the underlying pathogenesis.

KW - CXCR4

KW - Lymphoid neoplasm

KW - Lymphoplasmacytic lymphoma

KW - Monoclonal immunoglobulin M

KW - MYD88

UR - http://www.scopus.com/inward/record.url?scp=85016462940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016462940&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2017.02.028

DO - 10.1016/j.clml.2017.02.028

M3 - Article

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

ER -